Novo Nordisk

The Canadian researcher has just received the Frontiers of Knowledge Award for his work on anti-obesity drugs. However, he remains cautious about their use

As anti-obesity drugs gain traction and thinness is increasingly equated with health, the movement to accept diverse body types is being sidelined

The British drug agency is monitoring a possible increase in cases of the disease, although there is no data yet to warrant alarm

Novo Nordisk’s campaign, which aims to speak ‘without filters’ by declaring obesity a disease, has been strongly criticized on social media: ‘It’s indecent’

The next generation of treatments aims to help patients lose a quarter of their weight

Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new slimming drug CagriSema

As more pharmaceutical companies make inroads in the weight loss market, the two firms saw their shares fall more than 10% in the last month

Around the world, 100 companies have debuted weight-loss medications, which have become a multimillion-dollar business. Novo Nordisk’s Ozempic is currently the best-known, but it’s far from the only option

The semaglutide craze is a global phenomenon, but among its unwanted side effects is a premature aging of the face. Health professionals have found themselves administering anti-aging treatments to an ever-younger clientele

European share prices started the year on a positive note, trading at lower valuations, but analysts caution against confirming a trend shift

Citi estimates that the fight against obesity will generate revenue of $158 billion in 2035. The main risk for the sector is the difficulty in guaranteeing supply

The economic impact of obesity will reach losses of up to $4 trillion by 20235, or 3% of global GDP

During trials, patients showed reduced appetite and even an aversion towards food generally. This has the potential to affect giant companies such as Nestlé and Cadbury

The Danish pharmaceutical company has become the most valuable business in Europe thanks to its products that combat the disease, which the WHO believes has ‘acquired pandemic proportions’

The drugs include the blood thinner Eliquis, diabetes treatment Jardiance and eight other medications

In recent years, many patients who inject GLP-1 agonists have claimed to have lost their desire to drink. Now studies explain the scientific basis behind their experience, opening the door to other addiction treatments

The Danish drugmaker said Tuesday that pre-filled pens and vials of long- and short-acting insulins will see list price reductions